Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC in euthymic bipolar disorder
NCT03206463Phase 1Terminated
- Sponsor
- Yale University
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dronabinol in bipolar disorder (BD), sponsored by Yale University. Primary endpoint: Change in Verbal memory. Started Aug 2017; status: terminated.
02
Drugs
dronabinol
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03206463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206463.